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Chronic kidney disease (CKD) is associated with high morbidity and mortality and has high and 
increasing incidence worldwide. CKD is characterized by a reduction in glomerular filtration rate 
(GFR), but as GFR is difficult to measure directly, estimated glomerular filtration rate (eGFR) 
equations have been created to measure serum creatinine levels as a function of GFR. Some 
eGFR equations contain a racial multiplier that increases the eGFR of black patients, causing a 
spurious increase in reported kidney function. This study included a literature search that 
collected information on the rationale behind the multipliers usage and a survey that gathered 
information about healthcare professionals’ reception of the racial multiplier’s use. Use of the 
multiplier across the globe was found to be inconsistent. The survey found that there are many 
hospital systems across the US that report the racial multiplier and varying opinions among 
healthcare providers about its use. Applying the racial multiplier increases the eGFR of a patient 
by 16-21%, which may categorize a patient as being at a less severe stage of CKD than 
appropriate. The lack of consistency in the application of the racial multiplier, coupled with the 
understanding that race is not a biological characteristic, contraindicates its inclusion in a 
diagnostic algorithm. Inappropriate application of the racial multiplier causes delay to necessary 
treatments for affected patients. The inability to sort people into discrete racial categories on 
biological lines and lack of studies definitively supporting the racial multiplier calls for 
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Chronic kidney disease (CKD) is a serious and concerning worldwide healthcare concern. 
More than 15% of adults in the US are estimated to have CKD and 90% of the population with 
CKD is unaware of their condition.1 Worldwide incidence is climbing; in 2015, 1.2 million 
people died from kidney failure, a 35% increase from 2005. It is also estimated that 2.3-7.1 
million people with end-stage kidney disease (ESKD) die without access to dialysis and that 
number is estimated to double by 2030.2 CKD increases the risks associated with diabetes, 
hypertension, human immunodeficiency virus (HIV), and cardiovascular disease, increasing its 
impact on morbidity and mortality rates in all populations.2  
Patients who reach ESKD have greatly reduced renal function that is insufficient for 
sustaining life, requiring kidney replacement therapy, either in the form of kidney transplantation 
or renal dialysis. Both treatments are associated with high morbidity and significant financial 
burden.3 High-income countries spend greater than 2-3% of annual healthcare budgets on 
dialysis treatment although less than 0.03% of their population represents those who need 
treatment.2 In the US, the black population is the most affected, comprising only 13% of the total 
US population, but 30%  of the country’s ESKD patients.4 Other minority groups are 
disproportionally affected due to lack of early screenings and timely referral to treatment.5 
Because of high costs, people with ESKD in low-income populations may not have access to the 
treatment necessary to sustain kidney function, making the detection of early stages of utmost 
importance.  
CKD is characterized by a sustained reduction in the kidneys’ ability to filter plasma. It 
can occur as a secondary result of some diseases, most notably diabetes and hypertension, 
although glomerulonephritis, heart disease, exposure to toxic chemicals or drugs, and 
autoimmune conditions are also often implicated.6 These diseases cause CKD by placing 
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additional strain on the kidneys which damages their structure and functionality, reducing their 
ability to filter blood normally. CKD symptoms are non-specific in early stages and may not be 
detected without routine screening tests. The symptoms that appear as the disease progresses are 
due to the loss of kidney function and accumulation of uremic retention solutes, which can affect 
nearly all body systems. As CKD progresses, symptoms such as edema, proteinuria, anemia, 
CKD mineral bone disease, and metabolic acidosis occur. If untreated, CKD most often leads to 
death. Effective treatment strategies are centered around kidney replacement therapy, utilizing 
either renal dialysis or transplantation.3  
 CKD is diagnosed using the glomerular filtration rate (GFR), which is defined as the 
volume of plasma filtrate that passes through the glomeruli per minute.7  As GFR represents the 
filtration capabilities of the kidney, it is used to monitor kidney function in healthy patients as a 
screening test, as well as in patients who are taking certain medications or undergoing treatments 
that put them at risk for kidney damage. It is also used to stage the progression of CKD from its 
more moderate stages, where management of symptoms and preventing further renal damage is 
the focus, to ESKD, where the patient has minimal renal function and transplantation should be 
considered.8 The implications of CKD diagnosis includes high rates of both morbidity and 
mortality with few treatment options. Therefore, being able to monitor at-risk patients for 
changes in GFR to detect early stages of CKD is essential. GFR can be measured directly by 
measuring the urinary clearance of an exogenous filtrate injected into a patient’s bloodstream, 
generally inulin or iothalamate.9 This procedure is both complex and expensive, requiring an 
inpatient stay, IV administration of the exogenous filtrate, and careful urine collection.10 This 
method is considered the gold standard for assessing glomerular filtration rate, but it is relatively 
8 
 
difficult to perform on a large scale as a routine and screening test. Because of this, measured 
GFR is performed rarely and only as a confirmatory test or in research settings.   
Alternatively, GFR is routinely reported using the estimated glomerular filtration rate 
(eGFR). eGFRs measure the serum levels of an endogenous filtrate, most commonly creatinine, 
and use a calculation to estimate the patient’s GFR. Creatinine is used over other endogenous 
filtrates because it is produced by the body at a relatively constant rate as a product of muscle 
metabolism and is filtered at the glomerulus.11 The serum levels of creatinine are used in the 
eGFR equations as a function of the kidneys’ filtration rate. Creatinine is also cheaper to measure 
than other biomarkers that would have similar ability to estimate GFR, such as Cystatin C.9 The 
eGFR is a widely reported metric, as calculations are easily built into laboratory systems and can 
be reported on any test that measures creatinine levels without adding additional labor or 
processing time. Its accessibility and low cost allow eGFR to be built into metabolic panels used 
in routine bloodwork, giving clinicians a metric to monitor kidney function without the involved 
and time-consuming procedure of the measured GFR. It is especially valuable for monitoring the 
kidney function of patients who may not fall into traditional at-risk categories such as those with 
diabetes, hypertension, obesity, and cardiovascular disease. Monitoring eGFR in the general 
population as well as those at risk is essential because early stages of CKD are often 
asymptomatic.3 
eGFR values are calculated with a variety of different equations that have been developed 
in attempt to approximate the GFR as closely as possible. Using an endogenous filtrate is less 
precise, as any factor that affects the patient’s blood concentration of the filtrate will affect the 
eGFR. These are considered non-GFR determinants and the goal of the eGFR equations is to 
reduce the non-GFR determinants that may cause variations in eGFR that are not directly due to 
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kidney function. Because creatinine is a product of muscle breakdown, increased muscle mass 
causes a serum creatinine increase that results in an underestimation of GFR. Diet, especially 
meat intake, also affects serum creatinine levels. Variables that are most often used to correct for 
these non-GFR determinants are age, sex, weight, height, and race.8 
The first eGFR equation proposed by Cockcroft and Gault in 1976 did not propose a 
racial modifier, estimating creatinine clearance from serum creatinine with age, weight and  
sex.12 The racial modifier appeared first in the 1999 Modification of Diet in Renal Disease 
(MDRD) equation and then was continued into the 2009 Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) 
equations, see Table 1. The 
inclusion of race as a non-
GFR determinant originated 
from the idea that people 
who are black have 
increased muscle mass when 
compared to people of other 
races.15,16 The MDRD study cites this rationale for the inclusion of a modifier that increases the 
eGFR of black persons by an additional 18.1%,13 and was later increased to 21.1%.17 The CKD-
EPI study does not rationalize the use of a racial multiplier, but includes one that increases the 
eGFR of black persons by 15.9%.14 These are the two most commonly used eGFR calculations 
currently. Both are widely used and taught in clinical laboratory textbooks without rationale for 
the use of a racial multiplier.18–20 












𝑒𝐺𝐹𝑅 = 170 × [𝑆 ] .  × [𝑎𝑔𝑒] . × [𝑆𝑈𝑁] . × [𝐴𝑙𝑏] .  
× 0.762 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒 × 1.180 𝑖𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑖𝑠 𝑏𝑙𝑎𝑐𝑘 
Where SUN = serum urea nitrogen (mg/dL); Alb = serum albumin (g/dL) 
CKD-EPI 
(2009)14 








× 1.108 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒 × 1.159 𝑖𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑖𝑠 𝑏𝑙𝑎𝑐𝑘 




Because GFR is used to stage kidney disease and evaluate eligibility for participation in 
clinical trials and placement on a kidney transplant wait list, allowing race to modify this number 
requires significant justification as it can impact a patient’s criteria to receive proper treatment.22 
A race multiplier means that two people with the same serum creatinine levels would have 
different eGFR values if one individual were black 
and the other was not, even if they were identical in 
every other way, including muscle mass. The 
multiplier increases eGFR, which indicates better 
kidney health than if the multiplier were not applied. 
If it were applied erroneously, it may classify a 
patient in a less-advanced stage; see Table 2 for 
stages. This reclassification may delay access to proper treatment or approval for kidney 
transplant.  This is complicated in populations of mixed racial heritage, raising questions about 
whether or not the modifier should be applied to them at all, or if a reduced modifier is more 
appropriate.23 
The understanding that race is a social construct not a biological concept has been 
recognized in both social and medical disciplines.4,24–26 This challenges the legitimacy of using a 
racial correction in a calculation to determine something biologic, such as organ function. The 
use of this multiplier must be strongly supported in past studies to justify its continued use. In a 
healthcare system trending towards individualized care models there is no space for broad 
categories such as race with little relationship to biological makeup to be used in diagnostic 
methods. Medical treatment of patients of African descent has a sordid history of ulterior eugenic 
Table 2:  CKD Staging by eGFR21 
Stage eGFR 
1 ≥90 ml/min/1.73m2 
2 60-89 ml/min/1.73m2 
3 30-59 ml/min/1.73m2 
4 15-29 ml/min/1.73m2 
5 <15 ml/min/1.73m2 
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motives and any treatment of patients that differs on the basis of race must be supported strongly 
by the literature to ensure this trend is not perpetuated.5,27  
The University of Washington School of Medicine made headlines in June 2020 when its 
laboratories chose to discontinue the use of the race multiplier in its eGFR calculations.28 Since 
that time, a small number of other hospital systems have also publicly made this decision, but 
there is some hesitance among the medical community to abandon such a common practice. 
Some hospitals have made the decision to discontinue its use quietly, without releasing an 
official statement, making it difficult to quantify the percentage of hospitals that have moved 
away from this practice. The National Kidney Foundation and the American Society of 
Nephrology released a joint statement in July 2020 that they are committed to reevaluate the use 
of race in eGFR estimations in clinical practice across the United States.29 
This study evaluates the current literature on the use of the racial multiplier in eGFR 
calculation, how it is being used and the arguments for and against its use.  Current attitudes 
about the use of the racial multiplier among laboratorians, clinical laboratory educators, and 
physicians were also assessed. 
The purpose of this project is to understand the implications of the use of the racial 
multiplier on the quality of care received by the affected populations, specifically how its 
continued use may or may not cause harm to those that the multiplier is applied to. For this, we 
explored the global use of the racial modifier and the current trends and rationale behind the 
discontinuation of its use. The fundamental aim of this study is to shed light on the use of race  
as a modifier of a biologic process and the negative repercussions, if any, towards the health of 








The objective of the literature review portion of this study is to compile and summarize 
the summarize the available information about the use of the racial multiplier in eGFR, its 
scientific rationale and the clinical implications of its use. Does the literature support the use of a 
racial multiplier in creatinine-based eGFR calculations to provide the best approximation of renal 
function in black populations?  
The objective of the survey portion of this study is to gather information about the 
reporting of an eGFR accompanied by a racial multiplier in laboratories in the United States. Are 
laboratorians aware of its use and laboratories trending away from reporting a racial multiplier 
with eGFR results?  
Literature Search 
Searches for sources were conducted in PubMed Central, MEDLINE, and the Cochrane 
Library from August to September 2020. Key search terms included: Glomerular filtration rate, 
race/ethnicity, estimated glomerular filtration rates and African Americans, MDRD, CKD-EPI. 
Of the studies retrieved, only those that provided information pertaining to the objectives were 
retained. This primarily included studies that measured GFR and correlated it to eGFR in 
different populations of differing races or studies that looked at eGFR normal ranges in black 
populations outside of the United States. Studies focused on the prevalence of end-stage renal 
disease and CKD in those affected by the racial multiplier were also included. The sources cited 
in the relevant studies were scanned for other relevant studies that may not have been captured in 
the database searches.  
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As this review is focused on the use of a racial/ethnic modifier used in conjunction with 
creatinine-based eGFR calculations, studies focusing on the validity of creatinine-based eGFR 
calculations as an approximation for measured GFR for reasons other than the racial/ethnic 
multiplier were not included. Additionally, studies proposing other eGFR methodologies to 
replace creatinine-based estimation for reasons not directly related to the racial multiplier were 
not included. Preference was given to studies published since 2017, but some older landmark 
studies and the primary studies proposing major eGFR calculations were included. 
Information about the effectiveness of using the racial multiplier for black populations, 
the associated clinical consequences, and the rationale behind its usage historically was extracted 
from these publications. The information was then compiled to summarize the benefits and 
disadvantages a racial multiplier extends to the black population being evaluated for renal 
function and whether its continued use is supported. 
Survey 
This study also included a 
survey to assess current trends in 
clinical laboratories and opinions 
among clinical laboratory scientists 
across the States. The survey was 
created using Qualtrics and distributed 
via an anonymous link emailed to 
medical laboratory science program 
directors and affiliates. Emails of 
laboratory directors were also located 
Table 3: eGFR opinion survey questions 
Are you aware that estimated glomerular filtration 
rate (eGFR) us often reported as a different value 
based on the racial identity of the patient? 
Does your laboratory currently report a race 
coefficient for eGFR calculations? 
Has your laboratory reported a race coefficient with 
eGFR results in the past 5 years? 
Over the last 5 years, do you recall hearing of or 
participating in discussions about the use of race in 
the calculation of eGFR? 
Have you ever considered the scientific rationale or 
ethical implications concerning the use of race in the 
calculation of eGFR? 
Would you say you have a positive, negative, or 
neutral opinion on the use of the racial multiplier in 
eGFR calculations? 
Which of these categories best represents your role? 
Physician, Nurse, Medical technologist, Medical 
laboratory technician, supervisor, lab director, other 
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from online hospital directories. Approval of the retrieval of this de-identified information was 
granted from the Institutional Review Boards of the University of New Hampshire (IRB #8377).  
Of the 914 potential respondents contacted, 100 completed the survey from October 8th 2020 – 
November 13th 2020. The survey asked direct questions about whether participant’s institutions 
currently or recently reported a racial multiplier for eGFR, whether the laboratorian is aware of 
this practice, and collected their general opinion towards its usage. Information about general 
laboratory trends was  collected by the questions found in Table 3. Survey data was analyzed 
and stored in an Excel spreadsheet. Generation of figures was done primarily with formulas and 
charting tools in Excel, as well Visme, which was used to create map graphics from the data 






Global usage of the racial multiplier 
 In order to understand how the eGFR racial multiplier is used across the globe, literature 
search was used to identify countries where the racial modifier is applied when calculating eGFR 
(Figure 1). The most commonly used eGFR equations were developed and are used in the United 
States.13,14 Medical laboratories in Canada use the same multiplier for black populations as was 
developed from the studies conducted in the United States.30 Data on the usage of a racial 
multiplier in eGFR calculations in the Caribbean and Central American countries is scarce 
despite a higher percentage of people of African descent.31 Studies done in Saint Kitts and Nevis 
and Jamaica utilized the racial multiplier in the eGFR determination in black participants.32,33  
Figure 1. Countries where the racial modifier is applied when calculating eGFR for black populations.  Countries that use the 
modifier highlighted in orange and countries that do not in dark blue. Countries with no data are indicated in light blue. 
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 Comparative studies done between measured eGFR methods and iohexol clearance found 
that applying the racial multiplier to eGFR calculations overestimates kidney function compared 
to measured methods and should not be used with the Brazilian or Brazilian-African 
population.34,35 The multiplier has also been shown to be unnecessary for application to 
Uruguayan populations that identify as black.36 A study conducted in Colombia showed that 
eGFR measured with the MDRD equation and the corresponding racial modifier approximated 
other eGFR values determined from calculations that do not utilize a modifier for race, such as 
the Cockcroft-Gault and Cockcroft-Gault equation adjusted for body surface. However, it was 
determined that the CKD-EPI equation overestimates eGFR in the black population. Therefore, 
the racial modifier is suggested for the MDRD equation but not the CKD-EPI equation in this 
country.37 
 Usage of the racial multiplier in Europe varies from country to country. The United 
Kingdom uses the racial modifier, although the population to which it applies varies. Some 
studies correct by black racial identity and others by more specific ethnic groups, such as 
African-Caribbean ethnicity.38,39 The racial modifier is routinely applied to eGFR calculations in 
Croatia.40 Studies in Austria also include the racial multiplier as a variable, but a largely 
unutilized one due to a relatively small black population.41 Studies conducted in Germany do not 
routinely have a large enough black population to justify the routine use of the racial multiplier.42 
Similarly, studies conducted in Spain omitted the racial multiplier from eGFR calculations, even 
when using the MDRD or CKD-EPI equations.43,44 The racial multiplier is also omitted from the 
CKD-EPI equation in Belgium.45 Bulgarian studies do not include a racial multiplier.46 In 
Belarus, a modified version of the MDRD, known as the MDRD-MDPvD is used and no racial 
multiplier is necessary.47 In Sweden, the Lund-Malmo equation is favored for eGFR calculation 
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and relies on age, sex, and serum creatinine as its only variables; it does not contain a racial 
multiplier.48–50 Use of the racial multiplier is illegal in France due to unique laws surrounding the 
situations in which racial and ethnic categories can be collected and utilized.51,52 
Many Asian populations use modified versions of the CKD-EPI or MDRD because the 
equations created and validated in the United States do not represent GFR in their respective 
populations. In Japan, a correction coefficient of 0.813 is applied to the CKD-EPI equation 
because when uncorrected, it overestimates the eGFR in their population.53 Thailand utilizes a 
similar multiplier with the MDRD equation, except that it increases the eGFR by a multiplicative 
factor of 1.129 in Thai populations but does not include a racial modifier for black populations.54 
A modified equation for the CKD-EPI equation in Pakistani populations is best represented as  
0.686(CKD-EPI1.059), where CKD-EPI does not include a modifier for black populations.55 In 
China, the racial modifier not broadly used. It is applied to African-Americans, as that is the 
population for which the modifiers were validated when the equations were created, but the 
multiplier is not used with African, African-Asian or other black populations.54,56 A multiplier of 
1.23 applied to the MDRD has been validated for the native Chinese population57,58 The MDRD 
and CKD-EPI equations were validated in South Korean populations without the racial multiplier 
for black individuals.59,60 The racial multiplier is used exclusively for African-Americans in 
Turkey, as the multiplier was created and validated in the US, applying it to other black 
populations is contraindicated.61 The racial multiplier is applied to African-American 
populations only in Iran as well.62 The racial multiplier is applied to black populations in 
Oman.63 
The racial multiplier for black populations is used in Australia, but it is not acceptable to 
apply to native Australian populations.64 The CKD-EPI equation has been validated in New 
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Zealand without the addition 
of the racial multiplier. 65 
 Studies conducted in 
Côte d'Ivoire and the 
Democratic Republic of the 
Congo demonstrated that 
adjustment for race did not 
improve performance of the 
eGFR equations in their 
populations.66,67 A study in 
South Africa found that 
removing the racial 
multiplier decreased the bias 
between measured and 
estimated GFR.68 A similar 
study in Kenya determined that biases were eliminated when the race coefficient was removed 
from the eGFR equations.69 An Egyptian study found that MDRD and the accompanying racial 
multiplier were not as effective as the Cockcroft-Gault equation, which does not correct for 
race.70 The racial multiplier was demonstrated to overestimate GFR in Burkina Faso.71 The racial 
modifier is used in Morocco and Ethiopia, as a part of the eGFR calculations based off of the US 
studies and validations.72,73 
 When the eGFR is calculated and modified by race in the countries that utilize the racial 
modifier, Figure 2 represents the general process. Serum creatinine (Scr) is measured from a 
Figure 2. Flowchart depicting how eGFR is determined and how the racial 
multiplier, when used, is applied. Institutions that do not use the race multiplier 
proceed directly from eGFR equation output to CKD staging. 
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blood sample. One of many 
eGFR equations is then 
applied to the Scr value and 
an eGFR is determined. The 
most common eGFR 
equations worldwide are 
MDRD and CKD-EPI, both 
of which contain racial 
modifiers. If a different 
equation is used, the eGFR 
can be directly used to stage 
CKD. In the CKD-EPI and 
MDRD equations, the eGFR is increased by a multiplicative factor of 1.21 in the MDRD and 
1.18 in the CKD-EPI equations for patients that are black before CKD stage determination.13,14 
eGFR values are then used to categorize CKD by stages 1-5 (Figure 3). Stage 1 is the least 
severe and is considered kidney damage with a normal GFR (>90 mL/min/1.73m2). Stage 2 is 
characterized by kidney damage with mildly decreased GFR (60-89mL/min/1.73m2). Stage 3 is 
defined as a GFR of 30-59mL/min/1.73m2 with moderate reduction in kidney function. Stage 3 is 
often broken up into sub-stages, with 3a corresponding to a GFR of 45-59mL/min/1.73m2  and 
3b with a GFR of 30-44mL/min/1.73m2.74 Severe reduction in GFR (15-29mL/min/1.73m2 ) is 
considered stage 4, and a GFR below 15mL/min/1.73m2 is stage 5, also considered kidney failure 
or end-stage renal disease. 
Survey Results 
Figure 3. Classification of CKD by eGFR. Persistent proteinuria or other markers 




Of the 914 individuals contacted by email recruitment, 100 (10.9%) individuals agreed to 
participate (Figure 4a). The roles of participants is as follows: 33% physicians, 26% medical 
laboratory technologists/medical technician, 6% laboratory supervisors, 16% Medical laboratory 
science/Medical laboratory technician educational program director, 9% medical educators, and 
10% other or did not report a role (Figure 4b). Distribution of survey respondents across the 
United States is seen in Figure 4C. Eight participants were from New York, Seven from Texas, 
Six from New Hampshire, North Carolina, and Pennsylvania. Five responses were recorded from 
Figure 4. A) Comparison of survey respondents to number of people contacted by recruitment email. B)Role of respondents. 
Physicians in navy, medical technologists/technicians in orange, MLS/MLT program directors in yellow, educators in light 
blue, laboratory supervisors in grey, did not report in green. C) Location of participants in United States. Darker blue states 
indicate more participants, lightest blue indicates no participants. 
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Alaska and California. Four responses were recorded from Louisiana and Massachusetts.  
Arizona, Utah, and Ohio had three respondents each. Two responses were recorded from 
Colorado, Illinois, Indiana, Kansas, Missouri,  Rhode Island. South Carolina, and Tennessee. 
One response was collected from the following States/territories: Washington DC, Florida, Iowa, 
Maine, Maryland, Michigan, Minnesota, Mississippi, Nebraska, New Mexico, Oklahoma, Puerto 
Rico, Virginia, and Washington. Eight participants declined to report location. 
 Of those participants, 86 (91%) indicated that they were aware of the use of the racial 
multiplier in eGFR calculation (Figure 5a). When asked if the participant recalled hearing of or 
participating in discussions about the use of race in the calculation of eGFR, 35 (37.2%) 
responded “yes, many times”, 25 (26.6%) responded “once or few times”, 33 (35.1%) responded 
“No” (Figure 5b). 48 (64%) of recipients indicated that their lab currently reports a racial 
multiplier with eGFR calculations. 13 (17%) of recipients indicated that their lab does not 
currently report a racial coefficient with eGFR calculations, while 14 (19%) were unsure (Figure 
5c). Of the participants that responded that their lab does not currently report a race multiplier, 
8(62%) reported that they have reported a race multiplier within the last five years, 2(15%) 
reported that the race multiplier has not been in use for five years or longer (Figure 5d). When 
participants were asked if they had ever considered the scientific rationale or ethical implications 
concerning the use of race in the calculation of eGFR, 65 (69.9%) responded “yes”, 21 (22.6%) 
responded “no, never considered it”, 6 (6.5%) responded “No, unaware of its use” (Figure 5e). 
25 (26.9%) of participants said they had a positive opinion on the use of the racial multiplier, 35 
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(37.6%) said their opinion was neutral, 25 (26.9%) said their opinion was neutral, and 8 (8.6%) 
said they had no opinion (Figure 5f).   
 
 
Figure 5. A )Awareness of the usage of race in the determination of the eGFR among survey participants. B) Breakdown of 
participants by engagement in or recognition of conversations surrounding the use of the racial multiplier  C) Current use of the 
racial multiplier in eGFR reporting in the laboratories of the participants of this study D) Use of racial multiplier within the past 
five years among participants that  do not currently use the racial multiplier  E) Participants’ responses concerning previous 
considerations of the ethical or scientific implications of the use of the racial multiplier. F) Participants’ opinion of the use of the 




 The usage of the racial multiplier across the globe varies widely. Many countries that use 
it do so based on the results of the eGFR equation studies, which were calculated in an American 
population. Therefore, the racial multiplier may only be reflective of African Americans, as that 
was the only population included in the studies.14 Both the MDRD and the CKD-EPI equations 
propose the use of the multiplier for all black patients, although the multipliers were determined 
from African American populations,  neither study included a large population of black patients. 
14,75 The original MDRD study had only 197 black participants out of the total 1628 
participants.75 The CKD-EPI study was comprised of a 32% black population, but its external 
validation was conducted with only 10% black participants.14  These studies also lack defined 
parameters for determining what classifies a person as black or how to apply the multiplier to a 
person of mixed race. The complicated nature of determining who the multiplier should be 
applied to leads to varied interpretation of the racial multiplier’s application and inconsistent 
reporting practices across medical institutions, states, and countries. Some institutions apply the 
multiplier to all people who identify as black or are of African origin.  Other institutions apply 
the modifier to ethnic groups. In the UK, the multiplier is used for patients of Afro-Caribbean 
descent.39 Racial modifier reporting in both Iran and Turkey is limited to African-American 
populations, which likely indicates it is rarely reported.61,62 The lack of consistency among racial 
modifier reporting is a point of concern for quality of healthcare for the affected patients. 
 Many of the studies presented in this study were observed to lack consistency in the 
definitions of race and ethnicity. Race is broadly defined as a heritage-based association with a 
general geographic region accompanied by the physical phenotypes commonly attributed to the 
people from that region, most commonly skin color.76 Race was previously considered a 
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biological characteristic, and some of the earliest race theories suggested that races were either 
separate species or sub-species of humans. It was assumed members of individual races were 
genetically distinct from other races and genetic analysis could sort humans into discrete racial 
groups. Following the Human Genome Project, it is now understood that race is not a biological 
characteristic, as there are more differences in genetic makeup within a race than between 
races.77–81 If race were a concrete biological category, differences between other races would be 
expected to be greater than genetic variation within a racial group. Genetic commonalities within 
racial groups are more likely attributed to a likelihood to partner and mate with other members of 
the same race, producing offspring that may be more likely to have similar traits, but race itself is 
not an inherited, biological, genetic characteristic.82–85 
Ethnicity refers to a cultural group with some unifying characteristic, generally 
nationality, location, or tradition and a claimed kinship.76 Relevant examples include such as 
African Americans, afro-Caribbean, or Haitian which all may be considered individuals of black 
race but may not be genetically very similar. Neither ethnicity nor race are genetic 
characteristics, yet they may have an impact on glomerular filtration rate because there may be 
associated differences in diet or general body structure, but those are less attributed to the social 
constructs we consider as race or ethnicity. Other determinants my include access to early care, 
especially in the United States where access to healthcare is notably reduced in African-
American population and often regarded with a sense of distrust86,87. Rates of morbidity and 
mortality due to common diseases are higher in African Americans than nearly all other ethnic 
groups in the United States, but there is evidence that the health disparities are due to socially-
mediated factors such as poverty, poor access to care, discrimination, and differences in 
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treatment, and that differences in genetics due to racial heritage have minimal effect on these 
outcomes.85 
As race is not determined by discrete genetic differences, it begs the question of what the 
threshold of percent black race is necessary to qualify a patient for the racial multiplier. The first 
inclusions of race in medical care were strongly influenced by eugenic practices, so the inclusion 
of such a racial multiplier must be supported strongly by clinical studies and clearly defined as to 
who the multiplier should be applied to.88 This is complicated by the inability to sort all people 
into discrete racial groups and the increasingly large global population of individuals of mixed 
racial heritage. Historical classifications have utilized the principle of hypodescent which 
classifies a person as black if they have “one drop of African blood”89,90. It is unlikely that the 
most nominal African ancestry would affect the skeletal muscle significantly enough for the 
eGFR to require modification, but there must be criteria for determining who, if anyone, is 
benefitted most by the application of the modifier.  
 The MDRD and CKD-EPI being created in the United States means that they are best 
utilized in other countries where validation studies comparing measured GFR and eGFR of a 
representative population have been done. Because both equations are based off of endogenous 
creatinine levels, they are indirectly affected by muscle mass, diet, and sex. Meat consumption 
may result in higher levels of serum creatinine, producing a falsely decreased eGFR.91,92 Diets 
vary by country and region by culture and availability of food and diet is likely more tied to 
changes in endogenous creatinine levels than the racial identity of the patient. Dietary differences 
may be one explanation for why there are modifiers used in some east Asian countries that lower 
the eGFR when using the MDRD or CKD-EPI. Comparative mGFR and eGFR studies are 
necessary in all populations to ensure that the equations are valid for the population and the 
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racial modifier should be assessed to determine whether it improves the accuracy of the eGFR in 
the population it is applied to. 
 Usage of the racial modifier varies in the United States, but as recently as 2019 it was 
almost universally used. Many hospital systems, including Mass General/Brigham and Women’s 
Health System, University of Washington, and Vanderbilt University, all discontinued the use of 
the racial multiplier in summer 2020.28,93,94  The concurrence of the racial unrest happening in 
the United States and the removal of the racial multiplier also raised questions about whether the 
move to remove the racial multiplier was in haste. If the basis for this move was in an attempt to 
show support for the political movement or appear politically correct, it may actually have been 
harmful instead of a step towards achieving the desired equality.95 If the modifier makes the 
eGFR estimation more accurate, removing it without sufficient rationale is as problematic as 
using a multiplier when it is not needed. Removal of the racial multiplier lowers the eGFR, 
which may cause earlier referral for dialysis or transplantation which are risky procedures that 
are costly to the patient and should not be utilized unless there is no alternative. Alternatively, 
use of the racial multiplier on those that do not qualify, or if racial multiplier does not accurately 
represent a difference in glomerular function, it would increase the eGFR and delay the patients 
access to dialysis or renal transplantation. Because of the potential for harmful outcomes is 
substantial, it is essential that the racial modifier is only used if it truly provides a closer 
approximation of the patient’s GFR. 
 This study found that most of North America uses the racial multiplier. Canada has a 
similar racial profile compared to the United States, as well as similar dietary practices, 
expectably producing a population in which the American eGFR calculations would correlate 
well. No data was recovered for racial multiplier usage in Mexico, an unexpected finding, as 
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Mexico has the sixth highest CKD mortality rate in the world.96 In such a high risk country it 
would be expected there would be more studies on the potential effect that race or ethnicity may 
have on eGFR determination and therefore CKD diagnosis. Little data was found about the race 
multiplier in Caribbean countries, but would be a valuable population to study due to large 
percentages of mixed race populations.97 The two countries where data was found, St. Kitts and 
Nevis and Jaimaica, both used the racial multiplier with little explanation for why it was 
included. The geographical proximity to the other North American countries, or perhaps the 
influence of the American healthcare system in general may have prompted the use of the 
multiplier without comparative or validation studies. It is difficult to find data about the use of 
eGFR equations in the Caribbean countries and in South America, likely due to reduced access to 
laboratory services for routine creatinine testing even though CKD rates are high in both regions.  
Research on the validity of the racial multiplier would be beneficial to these populations, as 
mortality and morbidity rates are high to ESKD/HIV comorbidities and better management of 
renal health could lessen both economic and health burden in this region.98  
 A direct comparison study between the measured GFR and the eGFR done in Brazil 
demonstrated that the racial multiplier overestimates glomerular filtration rate, both with the 
general Brazilian population and with African-Brazilians. It is an important finding because 
Brazil is considered to be one of the most ethnically diverse countries on earth. In Brazil, race is 
also primarily determined by appearance, not by ancestry.99 This would complicate utilizing a 
racial multiplier because a patient’s identified race is not directly associated with the patients’ 
genetic makeup. In such a mixed population it would be difficult to determine to whom the 
multiplier should be applied, so determining that the racial multiplier is not a useful metric in this 
population eliminates such complications. Other populations compromised of mixed ethnic 
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backgrounds should consider similar comparative studies if they are routinely utilizing the racial 
multiplier.  
The European countries looked at in this study largely did not utilize the racial multiplier, 
specifically because the percentage of patients that identify as black is smaller than other regions 
where the multiplier is widely used. The process of validating the equations for use with the 
racial multiplier may be prohibitive to its routine use. Due to laws preventing the use of race or 
religion as a modifier of health care, the racial multiplier cannot be applied to black patients in 
France, even if it more accurately reflects their renal function.51 Countries surrounding France 
also notably do not use the racial multiplier, perhaps due to similar social pressures against using 
race as a modifier in the assessment of a physiologic process. A validation study done in Spain 
did not include any individuals of African descent.100 It would be unethical to use the racial 
multiplier in a population where it have not been validated. 
The low rate of the usage in other east Asian countries is likely due to a small percentage 
of black patients. Many Asian countries use modified eGFR equations because unmodified 
versions of the equations overestimate eGFR.53,55 It is interesting to note that these populations 
require a modifier to accurately represent GFR but it has not been widely considered to apply a 
reductive multiplier to the eGFR estimation of Asian populations in the United States. If the 
rationale for this modifier were based in race, it would make sense to apply it to all Asian 
populations, but the modifiers used in Asian eGFR calculations differ by country and are not 
universally applicable to all Asian countries.  
 Comparative studies done in Africa largely found that the racial multiplier overestimates 
the glomerular filtration rate, especially in Sub-Saharan Africa. Kenya and Morocco were the 
only two African countries using the racial multiplier identified in this study. Notably, no 
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measured GFR and eGFR comparison studies were found for these countries either.  Most of the 
countries in Africa that do not use the multiplier have performed and published comparative 
studies validating the eGFR equations without the racial multiplier against measured GFR. It is 
important to note that all studies directly comparing measured and estimated GFR in African 
populations found the racial multiplier to overestimate the glomerular filtration rate. If there is a 
biological difference in the GFR as a function of black race, it would be expected to be seen in 
African populations. The fact that the racial multiplier is not effective in this population indicates 
that the discrepancy between black patients’ eGFRs and other patients’ GFRs seen in the MDRD 
and CKD-EPI studies is unlikely to be directly attributed to race. There is a strong possibility 
that the difference in populations is associated with race, but a not a biological attribute due to 
race itself.  It is also important to note that the difference in eGFR by race is most commonly 
attributed to an increased in muscle mass in African Americans compared to other populations. 
In Sub-Saharan Africa, mean BMI and nourishment levels are expectedly lower, which may also 
attribute to a difference in the reported eGFR levels. 
  This aligns with the idea that race is not a biological characteristic, but a social construct. 
The differences seen in eGFR in two populations in the United States, black and non-black, 
could be attributed to race, but could also be attributed to differences in social and life 
experiences between these two groups that leads to differences in renal function. If the multiplier 
does not hold with other members of the same race in other countries, then it cannot be a 
function of race. It therefore has to be either the function of a biological characteristic present in 
a smaller ethnic groups, such as African Americans, or can be due to external stressors on that 
group of people that results in significant renal function. The racial multiplier does not make 
sense with the understanding that race is not a biological characteristic. However, even though 
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the basis of race is not biological, the social effects of being a minority in the United States 
extends into access to healthcare, and its social ramifications affect how people experience life, 
health, and healthcare. 
 The original MDRD and CKD-EPI cite differences in muscle mass as the rationale for a 
racial multiplier for the black population.14,75 Muscle mass is also affected by age and sex, the 
other most common variables in eGFR equations. The inclusion of race is supported by other 
studies that have found an increased muscle mass in African American populations.101–103 It has 
also been found that skeletal muscle mass decreases faster in aging African-Americans than 
people of other races.104 It would be expected that the racial modifier loses its accuracy as a 
patient ages and the difference in skeletal muscle mass between black patients and other patients 
decreases. In both the MDRD and CKD-EPI equations the racial multiplier is applied to the final 
product of the other variables and is a fixed variable, not affected by the age of the patient. This 
complicates the utilization of the racial multiplier, but the primary concerns against using it is 
that it does not accurately reflect a difference in renal function, has relatively unknown 
applications for mixed race populations, and has not been extensively studied in large black 
populations. 
The survey portion of this study was primarily sent to laboratory scientists, medical 
laboratory science program directors, and nephrologists associated with medical schools. 
Because emails for laboratory and medical professionals are most accessible to the public when 
associated with an academic program, most of the participants were from academic settings and 
may not be reflective of the general population. Professionals in academic fields may be more 
likely to be aware of and engaged in the current trends in medicine. Only 6% of the participants 
in this survey were unaware of the use of the racial multiplier for eGFR reporting, but it is likely 
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laboratory professionals not actively engaged in academic pursuits would be less aware of its 
use. The increased percentage of academic professionals likely also affected the response rate to 
the question about hearing or participating in discussions about the use of race in the calculation 
of eGFR. The use and discontinuation of the racial multiplier is a current topic of interest and is 
likely a point of discussion in many academic circles but may not be as commonly encountered 
in routine laboratory settings. This question was designed to assess whether participants simply 
know that the racial multiplier is used or if it is something that they are cognizant of its usage 
enough to be aware or engaged in conversations about the associated controversy. 
 Most of the respondents reported that their laboratory reported the race multiplier with 
eGFR. This demonstrates that the use of the racial multiplier is still widely in use in the United 
States, despite many reports of hospitals discontinuing its use. Of the participants that reported 
they were not using the racial multiplier, most of them reported that they had reported a race 
multiplier within the last five years, indicating that the decision to discontinue the multiplier’s 
use is primarily a movement of the past five years. Most regions of the United States were 
represented well in the survey, excepting the Northwestern states, although it is not expected that 
the usage varies greatly from the rest of the country. 
 One question on the survey asked participants to classify their opinion of the use of the 
racial multiplier as a positive opinion, neutral opinion, or negative opinion. The intended purpose 
of this question was to gather information about general opinions among participants about the 
use of the racial multiplier. However, these terms were poorly defined with no guidelines for 
what constitutes a positive or negative opinion. The responses were distributed following a 
normal curve and likely hold little significance to this study due to the poor question wording. 
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 When asked if they had considered the scientific rationale or ethical implications for the 
use of the racial multiplier, most of the participants responded that they have. However, 22.6% 
of participants that had responded that they were aware of the racial multiplier and had not ever 
considered the scientific or ethical implications of its use. It is possible that these individuals 
were introduced to the reasoning for the race multiplier’s inclusion at the same time as the eGFR 
equations themselves. However, most clinical chemistry textbooks do not include rationale for 
the inclusion of the racial multiplier in eGFR calculations.18,19,105 Having a significant portion of 
respondents not have considered how the multiplier came to be and how it affects care is 
concerning, as modifiers such as these must be carefully considered and scientifically supported 
to rationalize their use. The history of healthcare in the US is full of inequalities based in race, 
from studies that unfairly exploited racial minorities to eugenic medical practices. Preventing 
such disparities in healthcare and treatment practices between races is an active process requiring 
careful consideration and evaluation of all those involved.  
 Beyond the racial multiplier used in eGFR determination, there are other racial modifiers 
used in healthcare that have been called into question in recent years. Most similar is the Kidney 
Donor Risk Index (KDRI), where a potential donor is assessed for history of health complication, 
height and weight, race, and other factors to determine the likelihood that the transplant will fail. 
Potential donors that identify as black are assigned a higher risk of failure, although the initial 
study does not include rationale for this inclusion.106 This exacerbates the increased wait times 
for black kidney transplant recipients, as they are more likely to receive a kidney from a black 
donor and the use of the KDRI reduces the likelihood of finding a viable match.5 
 The Vaginal Birth after C Section (VBAC) algorithm is another predictive model that is 
modified by race or ethnicity. This equation predicts a lower likelihood of successful vaginal 
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delivery after C section from previous pregnancy in black and Latina women.107 Other 
determinants that indirectly attributed higher likelihood of success was insurance and marital 
status, although these determinants have not been integrated into the equation, as seen with 
race.108 Vaginal birth is less likely to have serious complications than a cesarean delivery, so the 
VBAC’s increased risk score for black and Latina patients must be weighed carefully.109  The 
inclusion of a race, a characteristic not firmly rooted in genetics, in the VBAC algorithm may 
exacerbate increased risk for childbirth complications in minority populations.110,111 
The American Heart Association (AHA) has a heart failure risk score used to predict the 
risk of death in admitted patients, intended to direct cardiac referral and allocation of resources. 
Higher scores indicate higher risk for death by heart failure and lower scores indicate lower risk. 
Without known rationale, non-black patients are assigned additional points, effectively 
increasing their perceived risk over a black patient.112 This channels resources to non-black 
patients and away from black patients who are already known to be at the highest risk for death 
by cardiovascular disease in the United States.113 
The American Academy of Pediatrics uses a calculator for estimating the probability of 
an urinary tract infection (UTI) in febrile, preverbal children (UTICalc) that uses race as a 
variable to determine whether a patient should be tested for a UTI. Race is used in conjunction 
with age, fever temperature and duration, and lack of identifiable fever source to determine the 
likelihood that the child should be tested for a UTI.114 Black patients are considered to be lower 
risk for UTI, so a black child who presents with UTI risk factors would require more risk factors 
to indicate testing for UTI. This can be harmful for black patients who do have UTIs and are 
delayed treatment because the calculator does not indicate that testing is necessary until a later 
stage than other non-black patients. 
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Isoniazid, one of the drugs of choice for tuberculosis treatment, has shown hepatoxicity that 
varies by racial background of the patient. It is metabolized by liver N-acetyltransferases (NAT). 
“Slow acetylaters” have a quantitative defect of the NAT enzyme that results in a higher 
concentration of the drug circulating in their bloodstream.115  Approximately 50 percent of 
Caucasians and African Americans are “slow acetylators” and therefore are more likely to 
experience hepatotoxicity, therefore requiring careful monitoring of the liver for development of 
hepatocellular liver damage. The remaining 50 percent of Caucasians and African Americans, as 
well as the majority of Asians, are “fast acetylators,” and can metabolize isoniazid three times 
faster than “slow acetylators.”116 While there is an association with increased risk in some ethnic 
groups, it still only comprises 50 percent of the population in these groups, therefore decreasing 
the amount of the of isoniazid prescribed for entire racial groups would not be appropriate. 
Therefore, it must be determined if the patient is truly a “slow acetylator” before modifying their 
treatment.  
 Racial modifiers have found their way into clinical and predictive algorithms across 
medical disciplines. These modifiers have the potential to overestimate or underestimate organ 
functionality or potential risk for a patient, which may cause harm to the patient due to delays in 
receiving necessary care or complications from unnecessary procedures or treatments. Therefore, 
assessing whether these multipliers are truly indicative of a physiological difference between 
racial groups is necessary. It is also necessary to have distinct guidelines for how to determine if 
a patient falls within a racial group. It is unlikely that hospital systems assigning race to a patient 
based upon a set of developed criteria would be well received, but allowing the patient to self-
assign race without full understanding of how their response could affect their care has ethical 
complications as well.  
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Furthermore, the lack of consistency between interpretation of which patient populations to 
apply the multiplier to further complicates the use of the multiplier. The discontinuation of eGFR 
racial multiplier usage in some but not all hospitals in the US means that a patient could switch 
hospital systems and suddenly their eGFR value might appear 15-21% different than their results 
from their previous healthcare provider. The difference in eGFR due to discontinuation of the 
racial multiplier is enough to change the patient’s CKD stage and may cause questions about 
how to proceed with treatment. If the patient was on the transplant list while at a hospital that 
does not use the racial multiplier and switched to a hospital that does, they would no longer be a 
candidate for transplantation. A study done at Brigham and Women’s hospital found that 
removing the racial multiplier from eGFR reporting reclassified 1 in 3 black patients to a more 
severe stage of CKD.93 The lack of consistent guidelines for use and application of the multiplier 
coupled with lack of evidence for a biological basis for race does not support the continued use 
of this multiplier. Modifying the process of estimating renal health by eGFR to eliminate the use 
of race would provide a better standard of care. Incorporation of skeletal mass directly in the 
eGFR equations would improve the efficacy of the multiplier for all racial groups and remove 
the need for a racial correction. Exploring alternative endogenous markers to calculate eGFR that 
are not affected by muscle mass or any traits that have been associate with racial characteristics 
would also eliminate need for the racial multiplier. Comparing an individual patient’s measured 
GFR and eGFR with and without the racial multiplier may also be beneficial to see if the 
modifier increases accuracy in that patient. This study demonstrates that current use of the racial 
multiplier is problematic due to the inability to create and assign racial categories based solely in 
genetic inheritance, current practices being based in racial self-identification from the patient, 
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lack of consistency among medical institutions, and the scarcity of studies directly comparing 
measured GFR and eGFR in black patients to evaluate the racial multiplier. 
Diagnostic medicine is most effective when the variables used give you information about an 
individual patient, but a patient’s race has no causative relationship to genetic makeup and 
thereby is not a reliable component of a diagnostic algorithm. In light of this, diagnostic 
medicine should always be trending towards more accurate markers of disease, eliminating 
extraneous and unrelated variables wherever possible. This study showed that race as a variable 
is problematic because populations cannot be discretely divided by race and therefore there is no 
basis for universal definition. This study also demonstrated that the use of the racial multiplier is 
not universal nor is it consistently applied even within the US. Such a lack of definitive 
categorization makes it an unreliable metric with the potential for great risk of adverse patient 







This study could have been improved with the addition of more specific questions based on 
participant’s role. Gathering information about teaching trends among educators, as well as 
information about if and how they educate medical and laboratory students about the racial 
multiplier  would provide important information about how health professionals are taught to 
think about the use of race in diagnostic procedures. Data from nephrologists on the clinical 
significance of the eGFR compared to other measurements of renal function as well as the direct 
influence of the eGFR on treatment would have supported the discussion on the direct effects of 
the racial multiplier on patient care. Assessing the usage of measured GFR versus eGFR among 
nephrologists would have been helpful to understand how often the eGFR is relied on without 
confirmatory testing.  Data from healthcare institutions or providers about how the racial 
modifier is applied and how racial identity of the patient is assessed or defined would be valuable 
to understand how such classifications are made and whether the process is highly variable 
between institutions. If an institute allows a patient to self-report race, data from patients being 
treated for kidney disease could be collected to determine their awareness that their identified 
race affects their care. 
Assessing the usage of the racial multiplier by state with respect to the percentage of black 
populations could be used to determine if the population of patients affected by the multiplier 
makes an institution more or less likely to utilize it. This study was limited by the number of 
participants and could not have effectively assessed the multiplier’s usage, as many states 
yielded only one participant. Increased participation and dispersion of participants would have 
made the sample more representative, as would increasing the number of non-academic 
participants.  Likewise, collecting information about eGFR vs measured GFR, methodology for 
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classifying patients by race, and overall usage data for the racial multiplier in other countries 
would support the discussion about worldwide practices concerning the racial multiplier.  
Assessing how the discontinuation of the racial multiplier at some institutions impacted 
patients experience and treatment options would be valuable for other institutions that are 
considering discarding the multiplier. Studying if and how patients’ treatment plans changed, 
how providers explained any changes to the patients, and how it was received by the patients are 
all data points of use. Promoting and encouraging hospitals to assess and study their use of race 
as a variable in diagnostic equations is an important step towards better quality of care as well as 
eradication of racism in healthcare. Assessing the use of race in the eGFR calculation could be 
done by measuring GFR alongside the eGFR in some patients to determine if the racial 
multiplier approximates the patients GFR more accurately. Researchers should prioritize creating 
equations for diagnoses based on objective variables, including assessing muscle mass or other 
determinants of endogenous creatine concentrations in place of race in eGFR calculation. 
As this study found that education about the use of the racial multiplier in eGFR calculation 
is overlooked, better teaching about race and how it is used in medicine is essential. Reducing 
racial disparities in healthcare relies on educating healthcare workers to think critically about 
race’s place in healthcare. Textbook writers and educators should be encouraged to include the 
scientific rationale when presenting diagnostic algorithms that are modified by race.  
There is much room for growth in diagnostic medicine where the use of race in medicine is 
concerned. More study of differences in access to healthcare or other factors that may lead to the 
discrepancies in health outcomes for patients in minority racial groups is necessary. Removing a 
nonspecific variable, like race, from a diagnostic equation can only serve to increase the quality 
of care. Race should not be a variable in a patient’s health, not in access to care, treatment plan, 
39 
 
or diagnostic algorithms. Removing race from the eGFR equation is a small but necessary step 










1.  Chronic Kidney Disease in the United States, 2019. Published March 13, 2019. Accessed 
September 2, 2020. https://www.cdc.gov/kidneydisease/publications-resources/2019-
national-facts.html 
2.  WHO | The global burden of kidney disease and the sustainable development goals. WHO. 
doi:10.2471/BLT.17.206441 
3.  Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. The Lancet. 
2017;389(10075):1238-1252. doi:10.1016/S0140-6736(16)32064-5 
4.  Norton JM, Moxey-Mims MM, Eggers PW, et al. Social Determinants of Racial 
Disparities in CKD. J Am Soc Nephrol. 2016;27(9):2576-2595. 
doi:10.1681/ASN.2016010027 
5.  Harding K, Mersha TB, Pham P-T, et al. Health Disparities in Kidney Transplantation for 
African Americans. Am J Nephrol. 2017;46(2):165-175. doi:10.1159/000479480 
6.  Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. 
2013;3(4):368-371. doi:10.1038/kisup.2013.79 
7.  Kaufman DP, Basit H, Knohl SJ. Physiology, Glomerular Filtration Rate (GFR). In: 
StatPearls. StatPearls Publishing; 2020. Accessed September 2, 2020. 
http://www.ncbi.nlm.nih.gov/books/NBK500032/ 
8.  Musso CG, Álvarez-Gregori J, Jauregui J, Macías-Núñez JF. Glomerular filtration rate 
equations: a comprehensive review. Int Urol Nephrol. 2016;48(7):1105-1110. 
doi:10.1007/s11255-016-1276-1 
9.  Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular 
filtration rate. Curr Opin Nephrol Hypertens. 2015;24(3):295–300. 
doi:10.1097/MNH.0000000000000115 
10.  Bjornstad P, Karger AB, Maahs DM. Measured GFR in Routine Clinical Practice – The 
Promise of Dried Blood Spots. Adv Chronic Kidney Dis. 2018;25(1):76-83. 
doi:10.1053/j.ackd.2017.09.003 
11.  Agarwal R. Estimating GFR from serum creatinine concentration: Pitfalls of GFR-
estimating equations. Am J Kidney Dis. 2005;45(3):610-613. 
doi:10.1053/j.ajkd.2005.01.010 
12.  Cockcroft D, Gault M. Cockcroft DW, Gault MHPrediction of creatine clearance from 
serum creatinine. Nephron 16: 31-41. Nephron. 1976;16:31-41. doi:10.1159/000180580 
13.  Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to 
estimate glomerular filtration rate from serum creatinine: a new prediction equation. 
41 
 
Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-
470. doi:10.7326/0003-4819-130-6-199903160-00002 
14.  Levey AS, Stevens LA, Schmid CH, et al. A New Equation to Estimate Glomerular 
Filtration Rate. Ann Intern Med. 2009;150(9):604-612. 
15.  Levey AS, Inker LA, Coresh J. GFR Estimation: From Physiology to Public Health. Am J 
Kidney Dis Off J Natl Kidney Found. 2014;63(5):820-834. doi:10.1053/j.ajkd.2013.12.006 
16.  Gallagher D, Visser M, De Meersman RE, et al. Appendicular skeletal muscle mass: 
effects of age, gender, and ethnicity. J Appl Physiol Bethesda Md 1985. 1997;83(1):229-
239. doi:10.1152/jappl.1997.83.1.229 
17.  Swart MJ, Bekker AM, Malan JJ, Meiring A, Swart Z, Joubert G. The simplified 
modification of diet in renal disease equation as a predictor of renal function after 
coronary artery bypass graft surgery. Cardiovasc J Afr. 2010;21(1):9-12. 
18.  Strasinger S, Di Lorenzo M. Urinalysis and Body Fluids. 6th ed. F.A. Davis Company; 
2014. 
19.  Mundt LA, Shanahan K, Graff L. Graff’s Textbook of Urinalysis and Body Fluids.; 2016. 
20.  Burtis CA, Bruns DE, Sawyer BG, Tietz NW. Tietz Fundamentals of Clinical Chemistry 
and Molecular Diagnostics.; 2015. Accessed October 24, 2020. 
https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&A
N=1167481 
21.  CDC - Chronic Kidney Disease - FAQ. Accessed October 14, 2020. 
https://nccd.cdc.gov/CKD/help.aspx?section=F#3 
22.  Eneanya ND, Yang W, Reese PP. Reconsidering the Consequences of Using Race to 
Estimate Kidney Function. JAMA. 2019;322(2):113-114. doi:10.1001/jama.2019.5774 
23.  Udler MS, Nadkarni GN, Belbin G, et al. Effect of Genetic African Ancestry on eGFR and 
Kidney Disease. J Am Soc Nephrol JASN. 2015;26(7):1682-1692. 
doi:10.1681/ASN.2014050474 
24.  Fontanarosa PB, Bauchner H. Race, Ancestry, and Medical Research. JAMA. 
2018;320(15):1539-1540. doi:10.1001/jama.2018.14438 
25.  Ifekwunigwe JO, Wagner JK, Yu J-H, Harrell TM, Bamshad MJ, Royal CD. A Qualitative 
Analysis of How Anthropologists Interpret the Race Construct. Am Anthropol. 
2017;119(3):422-434. doi:10.1111/aman.12890 
26.  Norris KC, Williams SF, Rhee CM, et al. Hemodialysis Disparities in African Americans: 




27.  TUSKEGEE AND THE HEALTH OF BLACK MEN. Accessed October 26, 2020. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258045/ 
28.  UW Medicine to exclude race from calculation of eGFR (measure of kidney function) | 
Department of Medicine | University of Washington. Accessed September 2, 2020. 
https://medicine.uw.edu/news/uw-medicine-exclude-race-calculation-egfr-measure-
kidney-function 
29.  Establishing a Task Force to Reassess the Inclusion of Race in Diagnosing Kidney 
Diseases. National Kidney Foundation. Published July 2, 2020. Accessed September 2, 
2020. https://www.kidney.org/news/establishing-task-force-to-reassess-inclusion-race-
diagnosing-kidney-diseases 
30.  Guideline for the Transition from the MDRD to the CKD-EPI Equation for the 
Calculation of an Estimated Glomerular Filtration Rate (eGFR), and its Interpretation in 
Concert with the Urine Albumin/Creatinine Ratio (ACR). Published online April 2015. 
Accessed October 7, 2020. https://oaml.com/wp-
content/uploads/2016/05/OAMLeGFREPIGuidelineFinal2015.pdf 
31.  Patterson TR, Kelley RDG. Unfinished Migrations: Reflections on the African Diaspora 
and the Making of the Modern World. Afr Stud Rev. 2000;43(1):11-45. 
doi:10.2307/524719 
32.  Ferguson T, Tulloch-Reid M, Younger-Coleman N, et al. Prevalence of Chronic Kidney 
Disease among Patients Attending a Specialist Diabetes Clinic in Jamaica. West Indian 
Med J. 2015;64(3):201-208. doi:10.7727/wimj.2014.084 
33.  Crews DC, Campbell KN, Liu Y, Bussue O, Dawkins I, Young BA. Chronic kidney 
disease and risk factor prevalence in Saint Kitts and Nevis: a cross-sectional study. BMC 
Nephrol. 2017;18. doi:10.1186/s12882-016-0424-2 
34.  Rocha AD, Garcia S, Santos AB, et al. No Race-Ethnicity Adjustment in CKD-EPI 
Equations Is Required for Estimating Glomerular Filtration Rate in the Brazilian 
Population. International Journal of Nephrology. 
doi:https://doi.org/10.1155/2020/2141038 
35.  Zanocco JA, Nishida SK, Passos MT, et al. Race adjustment for estimating glomerular 
filtration rate is not always necessary. Nephron Extra. 2012;2(1):293-302. 
doi:10.1159/000343899 
36.  Lujambio I, Sottolano M, Luzardo L, et al. Estimation of Glomerular Filtration Rate Based 
on Serum Cystatin C versus Creatinine in a Uruguayan Population. Int J Nephrol. 
2014;2014:837106. doi:10.1155/2014/837106 
37.  Nieto-Cárdenas OA, Serna-Flórez J, Nieto-Cárdenas OA, Serna-Flórez J. Glomerular 




38.  Carter JL, Stevens PE, Irving JE, Lamb EJ. Estimating glomerular filtration rate: 
comparison of the CKD-EPI and MDRD equations in a large UK cohort with particular 
emphasis on the effect of age. QJM Int J Med. 2011;104(10):839-847. 
doi:10.1093/qjmed/hcr077 
39.  Kilpatrick ES, Verrill H, National Clinical Biochemistry Audit Group. A national audit of 
estimated glomerular filtration rate and proteinuria reporting in the UK. Ann Clin 
Biochem. 2011;48(Pt 6):558-561. doi:10.1258/acb.2011.011083 
40.  Biljak VR, Honović L, Matica J, Krešić B, Vojak SŠ. The role of laboratory testing in 
detection and classification of chronic kidney disease: national recommendations. 
Biochem Medica. 2017;27(1):153-176. doi:10.11613/BM.2017.019 
41.  Klöckl M-C, Kasparek A-K, Riedl JM, et al. Estimation versus measurement of the 
glomerular filtration rate for kidney function assessment in patients with cancer 
undergoing cisplatin-based chemotherapy. Sci Rep. 2020;10(1):11219. 
doi:10.1038/s41598-020-68010-5 
42.  Schwandt A, Denkinger M, Fasching P, et al. Comparison of MDRD, CKD-EPI, and 
Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large 
cohort with diabetes. J Diabetes Complications. 2017;31(9):1376-1383. 
doi:10.1016/j.jdiacomp.2017.06.016 
43.  Gràcia-Garcia S, Montañés-Bermúdez R, Morales-García LJ, et al. Current use of 
equations for estimating glomerular filtration rate in Spanish laboratories. Nefrol 
Publicacion Of Soc Espanola Nefrol. 2012;32(4):508-516. 
doi:10.3265/Nefrologia.pre2012.Mar.11375 
44.  Romero-Aroca P, Baget-Bernaldiz M, Navarro-Gil R, et al. Glomerular Filtration Rate 
and/or Ratio of Urine Albumin to Creatinine as Markers for Diabetic Retinopathy: A Ten-
Year Follow-Up Study. Journal of Diabetes Research. 
doi:https://doi.org/10.1155/2018/5637130 
45.  Delanaye P, Cavalier E, Morel J, et al. Detection of decreased glomerular filtration rate in 
intensive care units: serum cystatin C versusserum creatinine. BMC Nephrol. 
2014;15(1):9. doi:10.1186/1471-2369-15-9 
46.  Mihailov R, Stoeva D, Pencheva B. Estimation of glomerular filtration rate by different 
formulas. Nephrol Dial Transplant. 2014;20:20-30. 
47.  Pereverzeva EV, Gulko AY, Vabishevich YE, Welcome MO, Sikorsky AV, Pereverzev 
VA. Comparison of Different Methods of Glomerular Filtration Rate in Young Males with 
Arterial Hypertension. 2018;15:6. 
48.  Nyman U, Grubb A, Larsson A, et al. The revised Lund-Malmö GFR estimating equation 
outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish 




49.  Evans M, van Stralen KJ, Schön S, et al. Glomerular filtration rate-estimating equations 
for patients with advanced chronic kidney disease. Nephrol Dial Transplant Off Publ Eur 
Dial Transpl Assoc - Eur Ren Assoc. 2013;28(10):2518-2526. doi:10.1093/ndt/gft226 
50.  Trocchi P, Girndt M, Scheidt-Nave C, Markau S, Stang A. Impact of the estimation 
equation for GFR on population-based prevalence estimates of kidney dysfunction. BMC 
Nephrol. 2017;18(1):341. doi:10.1186/s12882-017-0749-5 
51.  Rivenbark J, Ichou M. Discrimination in healthcare as a barrier to care: experiences of 
socially disadvantaged populations in France from a nationally representative survey. 
BMC Public Health. 2020;20. doi:10.1186/s12889-019-8124-z 
52.  Biljak VR, Aakre KM, Yucel D, Bargnoux A-S, Cristol J-P, Piéroni L. A Pathway to 
National Guidelines for Laboratory Diagnostics of Chronic Kidney Disease – Examples 
from Diverse European Countries. EJIFCC. 2017;28(4):289-301. 
53.  Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD 
Epidemiology Collaboration (CKD-EPI) Equation for Japanese: Accuracy and Use for 
Population Estimates. Am J Kidney Dis. 2010;56(1):32-38. doi:10.1053/j.ajkd.2010.02.344 
54.  Praditpornsilpa K, Townamchai N, Chaiwatanarat T, et al. The need for robust validation 
for MDRD-based glomerular filtration rate estimation in various CKD populations. 
Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 
2011;26(9):2780-2785. doi:10.1093/ndt/gfq815 
55.  Jessani S, Levey AS, Bux R, et al. Estimation of GFR in South Asians: A Study From the 
General Population in Pakistan. Am J Kidney Dis Off J Natl Kidney Found. 2014;63(1):49-
58. doi:10.1053/j.ajkd.2013.07.023 
56.  Liu X, Xu H, Zheng Z, et al. Estimating glomerular filtration rates in elderly Chinese 
patients with chronic kidney disease: performance of six modified formulae developed in 
Asian populations. Clin Interv Aging. 2013;8:899-904. doi:10.2147/CIA.S47009 
57.  Ma Y-C, Zuo L, Chen J-H, et al. Modified glomerular filtration rate estimating equation 
for Chinese patients with chronic kidney disease. J Am Soc Nephrol JASN. 
2006;17(10):2937-2944. doi:10.1681/ASN.2006040368 
58.  Rule AD, Teo BW. GFR Estimation in Japan and China: What Accounts for the 
Difference? Am J Kidney Dis Off J Natl Kidney Found. 2009;53(6):932-935. 
doi:10.1053/j.ajkd.2009.02.011 
59.  Ji M, Lee Y-H, Hur M, et al. Comparing Results of Five Glomerular Filtration Rate-
Estimating Equations in the Korean General Population: MDRD Study, Revised Lund-




60.  Jeong T-D, Lee W, Yun Y-M, Chun S, Song J, Min W-K. Development and validation of 
the Korean version of CKD-EPI equation to estimate glomerular filtration rate. Clin 
Biochem. 2016;49(9):713-719. doi:10.1016/j.clinbiochem.2016.01.023 
61.  Süleymanlar G, Utaş C, Arinsoy T, et al. A population-based survey of Chronic REnal 
Disease In Turkey—the CREDIT study. Nephrol Dial Transplant. 2011;26(6):1862-1871. 
doi:10.1093/ndt/gfq656 
62.  Hosseinpanah F, Kasraei F, Nassiri AA, Azizi F. High prevalence of chronic kidney 
disease in Iran: a large population-based study. BMC Public Health. 2009;9(1):44. 
doi:10.1186/1471-2458-9-44 
63.  Mula-Abed W-AS, Al Rasadi K, Al-Riyami D. Estimated Glomerular Filtration Rate 
(eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and 
its Impact on Clinical Practice. Oman Med J. 2012;27(2):108-113. 
doi:10.5001/omj.2012.23 
64.  Maple‐Brown LJ, Ekinci EI, Hughes JT, et al. Performance of formulas for estimating 
glomerular filtration rate in Indigenous Australians with and without Type 2 diabetes: the 
eGFR Study. Diabet Med. 2014;31(7):829-838. doi:10.1111/dme.12426 
65.  Gr J. Adventures with Creatinine and eGFR - A National, International and Personal Story 
- AACB Roman Lecture 2014. Clin Biochem Rev. 2015;36(2):75-82. 
66.  Bukabau JB, Yayo E, Gnionsahé A, et al. Performance of creatinine- or cystatin C–based 
equations to estimate glomerular filtration rate in sub-Saharan African populations. Kidney 
Int. 2019;95(5):1181-1189. doi:10.1016/j.kint.2018.11.045 
67.  Bukabau JB, Sumaili EK, Cavalier E, et al. Performance of glomerular filtration rate 
estimation equations in Congolese healthy adults: The inopportunity of the ethnic 
correction. PLoS ONE. 2018;13(3). doi:10.1371/journal.pone.0193384 
68.  van Deventer HE, George JA, Paiker JE, Becker PJ, Katz IJ. Estimating glomerular 
filtration rate in black South Africans by use of the modification of diet in renal disease 
and Cockcroft-Gault equations. Clin Chem. 2008;54(7):1197-1202. 
doi:10.1373/clinchem.2007.099085 
69.  Wyatt CM, Schwartz GJ, Ong’or WO, et al. Estimating Kidney Function in HIV-Infected 
Adults in Kenya: Comparison to a Direct Measure of Glomerular Filtration Rate by 
Iohexol Clearance. PLOS ONE. 2013;8(8):e69601. doi:10.1371/journal.pone.0069601 
70.  Zaki T, Samir A, Mohammed Rashid T, Galal H, Samir W. Assessment of estimated GFR 
and clinical predictors of contrast induced nephropathy among diabetic patients 




71.  George JA, Brandenburg J-T, Fabian J, et al. Kidney damage and associated risk factors in 
rural and urban sub-Saharan Africa (AWI-Gen): a cross-sectional population study. Lancet 
Glob Health. 2019;7(12):e1632-e1643. doi:10.1016/S2214-109X(19)30443-7 
72.  Adugna T, Merga H, Gudina EK. Impaired glomerular filtration rate, high grade 
albuminuria and associated factors among adult patients admitted to tertiary Hospital in 
Ethiopia. BMC Nephrol. 2018;19(1):345. doi:10.1186/s12882-018-1153-5 
73.  Benghanem Gharbi M, Elseviers M, Zamd M, et al. Chronic kidney disease, hypertension, 
diabetes, and obesity in the adult population of Morocco: how to avoid “over”- and 
“under”-diagnosis of CKD. Kidney Int. 2016;89(6):1363-1371. 
doi:10.1016/j.kint.2016.02.019 
74.  Polkinghorne KR. Controversies in Chronic Kidney Disease Staging. Clin Biochem Rev. 
2011;32(2):55-59. 
75.  Levey AS. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum 
Creatinine: A New Prediction Equation. Ann Intern Med. 1999;130(6):461. 
doi:10.7326/0003-4819-130-6-199903160-00002 
76.  James M, Burgos A. Race. In: Zalta EN, ed. The Stanford Encyclopedia of Philosophy. 
Summer 2020. Metaphysics Research Lab, Stanford University; 2020. Accessed 
December 9, 2020. https://plato.stanford.edu/archives/sum2020/entries/race/ 
77.  Mccann-Mortimer P, Augoustinos M, Lecouteur A. ‘Race’ and the Human Genome 
Project: Constructions of Scientific Legitimacy. Discourse Soc. 2004;15(4):409-432. 
doi:10.1177/0957926504043707 
78.  Callister P, Didham R. Who are we?: The human genome project, race and ethnicity. Soc 
Policy J N Z. Published online August 1, 2009. 
79.  Race. Genome.gov. Accessed December 10, 2020. https://www.genome.gov/genetics-
glossary/Race 
80.  Hood L, Rowen L. The Human Genome Project: big science transforms biology and 
medicine. Genome Med. 2013;5(9):79. doi:10.1186/gm483 
81.  Templeton AR. Biological Races in Humans. Stud Hist Philos Biol Biomed Sci. 
2013;44(3):262-271. doi:10.1016/j.shpsc.2013.04.010 
82.  Bittles AH. Endogamy, consanguinity and community genetics. J Genet. 2002;81(3):91-
98. doi:10.1007/BF02715905 
83.  Whitmeyer JM. Endogamy as a Basis for Ethnic Behavior. Sociol Theory. 1997;15(2):162-
178. doi:10.1111/0735-2751.00030 




85.  The Use of Racial, Ethnic, and Ancestral Categories in Human Genetics Research. Am J 
Hum Genet. 2005;77(4):519-532. doi:10.1086/491747 
86.  Frakt A. Bad Medicine: The Harm That Comes From Racism. The New York Times. 
https://www.nytimes.com/2020/01/13/upshot/bad-medicine-the-harm-that-comes-from-
racism.html. Published January 13, 2020. Accessed December 10, 2020. 
87.  Jacobs EA, Rolle I, Ferrans CE, Whitaker EE, Warnecke RB. Understanding African 
Americans’ Views of the Trustworthiness of Physicians. J Gen Intern Med. 
2006;21(6):642-647. doi:10.1111/j.1525-1497.2006.00485.x 
88.  Mohsen H. Race and Genetics: Somber History, Troubled Present. Yale J Biol Med. 
2020;93(1):215-219. 
89.  One drop & one hate. American Academy of Arts & Sciences. Accessed December 10, 
2020. https://www.amacad.org/publication/one-drop-one-hate 
90.  Hickman CB. The Devil and the One Drop Rule: Racial Categories, African Americans, 
and the U.S. Census. Mich Law Rev. 1997;95(5):1161. doi:10.2307/1290008 
91.  Pimenta E, Jensen M, Jung D, Schaumann F, Boxnick S, Truebel H. Effect of Diet on 
Serum Creatinine in Healthy Subjects During a Phase I Study. J Clin Med Res. 
2016;8(11):836-839. doi:10.14740/jocmr2738w 
92.  Nair S, O’Brien SV, Hayden K, et al. Effect of a cooked meat meal on serum creatinine 
and estimated glomerular filtration rate in diabetes-related kidney disease. Diabetes Care. 
2014;37(2):483-487. doi:10.2337/dc13-1770 
93.  Ahmed S, Nutt CT, Eneanya ND, et al. Examining the Potential Impact of Race Multiplier 
Utilization in Estimated Glomerular Filtration Rate Calculation on African-American Care 
Outcomes. J Gen Intern Med. Published online October 15, 2020. doi:10.1007/s11606-
020-06280-5 
94.  Eliminating Race as a Variable in Estimating Kidney Function. Vanderbilt Discover. 
Published July 29, 2020. Accessed December 10, 2020. 
https://discover.vumc.org/2020/07/eliminating-race-as-a-variable-in-estimating-kidney-
function/ 
95.  Scrutiny on Race-Base eGFR Correction Factors. Clinical Laboratory News. 
96.  Vasquez-Jimenez E, Madero M. Global Dialysis Perspective: Mexico. Kidney360. 
2020;1(6):534-537. doi:10.34067/KID.0000912020 
97.  England S. Mixed and multiracial in Trinidad and Honduras: rethinking mixed-race 




98.  Jose S, Hamzah L, Jones R, et al. Chronic Kidney Disease Risk in African and Caribbean 
Populations With HIV. J Infect Dis. 2018;218(11):1767-1772. doi:10.1093/infdis/jiy397 
99.  Nations U. Racial Discrimination and Miscegenation: The Experience in Brazil. United 
Nations. Accessed December 6, 2020. https://www.un.org/en/chronicle/article/racial-
discrimination-and-miscegenation-experience-brazil 
100.  Teruel Briones JL, Teruel Briones JL, Gomis Couto A, et al. Validation of the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in advanced chronic 
renal failure. Nefrol Engl Ed. 2011;31(6):677-682. 
doi:10.3265/Nefrologia.pre2011.Sep.11014 
101.  Ortiz O, Russell M, Daley TL, et al. Differences in skeletal muscle and bone mineral mass 
between black and white females and their relevance to estimates of body composition. 
Am J Clin Nutr. 1992;55(1):8-13. doi:10.1093/ajcn/55.1.8 
102.  Heymsfield SB, Stanley A, Pietrobelli A, Heo M. Simple Skeletal Muscle Mass 
Estimation Formulas: What We Can Learn From Them. Front Endocrinol. 2020;11. 
doi:10.3389/fendo.2020.00031 
103.  Araujo AB, Chiu GR, Kupelian V, et al. Lean mass, muscle strength, and physical 
function in a diverse population of men: a population-based cross-sectional study. BMC 
Public Health. 2010;10(1):508. doi:10.1186/1471-2458-10-508 
104.  Silva AM, Shen W, Heo M, et al. Ethnicity-Related Skeletal Muscle Differences Across 
the Lifespan. Am J Hum Biol Off J Hum Biol Counc. 2010;22(1):76-82. 
doi:10.1002/ajhb.20956 
105.  Bishop ML, Fody EP, Schoeff LE. Clinical Chemistry: Principles, Techniques, and 
Correlations. Lippincott Williams & Wilkins; 2013. 
106.  Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for 
deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88(2):231-
236. doi:10.1097/TP.0b013e3181ac620b 
107.  Grobman WA, Lai Y, Landon MB, et al. Development of a Nomogram for Prediction of 
Vaginal Birth After Cesarean Delivery. Obstet Gynecol. 2007;109(4):806–812. 
doi:10.1097/01.AOG.0000259312.36053.02 
108.  Landon MB, Leindecker S, Spong CY, et al. The MFMU Cesarean Registry: factors 
affecting the success of trial of labor after previous cesarean delivery. Am J Obstet 
Gynecol. 2005;193(3 Pt 2):1016-1023. doi:10.1016/j.ajog.2005.05.066 
109.  Keag OE, Norman JE, Stock SJ. Long-term risks and benefits associated with cesarean 
delivery for mother, baby, and subsequent pregnancies: Systematic review and meta-
analysis. PLoS Med. 2018;15(1). doi:10.1371/journal.pmed.1002494 
49 
 
110.  Racial and Ethnic Disparities Continue in Pregnancy-Related Deaths | CDC Online 
Newsroom | CDC. Published September 6, 2019. Accessed December 11, 2020. 
https://www.cdc.gov/media/releases/2019/p0905-racial-ethnic-disparities-pregnancy-
deaths.html 
111.  Howell EA. Reducing Disparities in Severe Maternal Morbidity and Mortality. Clin 
Obstet Gynecol. 2018;61(2):387-399. doi:10.1097/GRF.0000000000000349 
112.  Peterson Pamela N., Rumsfeld John S., Liang Li, et al. A Validated Risk Score for In-
Hospital Mortality in Patients With Heart Failure From the American Heart Association 
Get With the Guidelines Program. Circ Cardiovasc Qual Outcomes. 2010;3(1):25-32. 
doi:10.1161/CIRCOUTCOMES.109.854877 
113.  Brewer LC, Cooper LA. Race, Discrimination, and Cardiovascular Disease. AMA J Ethics. 
2014;16(6):455-460. doi:10.1001/virtualmentor.2014.16.6.stas2-1406. 
114.  Development and Validation of a Calculator for Estimating the Probability of Urinary 
Tract Infection in Young Febrile Children. Accessed December 6, 2020. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137527/ 
115.  Wang P, Pradhan K, Zhong X, Ma X. Isoniazid metabolism and hepatotoxicity. Acta 
Pharm Sin B. 2016;6(5):384-392. doi:10.1016/j.apsb.2016.07.014 
116.  fast_vs_slow_acetylators [TUSOM | Pharmwiki]. Accessed December 6, 2020. 
http://tmedweb.tulane.edu/pharmwiki/doku.php/fast_vs_slow_acetylators 
 
